COMMUNIQUÉS West-GlobeNewswire

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
03/06/2026
Novo Nordisk launches Wegovy ® pill in the United Arab Emirates today Wegovy ® pill is indicated to reduce excess body weight and maintain weight reduction long-term Wegovy ® pill, providing a mean weight loss of 17%, [...]
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 24 juin 2026 et désignation d’un mandataire ad hoc
03/06/2026
Communiqué de presse Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 24 juin 2026 et désignation d’un mandataire ad hoc 3 juin 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
03/06/2026
Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease [...]
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
03/06/2026
Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative June 3, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA ( [...]
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
03/06/2026
BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that updated data [...]
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
03/06/2026
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucocorticoid-related [...]
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
03/06/2026
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating [...]
DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide
03/06/2026
Châtillon, France, le 02 juin (22 :30 CEST) 2026 DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN ® Peanut chez les nourrissons âgés de 6 à 12 mois [...]
Fortrea to Attend Jefferies Global Healthcare Conference
03/06/2026
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor [...]
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
02/06/2026
Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a [...]
Nanobiotix fait le point sur sa tresorerie et son activite operationnelle pour le premier trimestre 2026
02/06/2026
Réalisation d’une augmentation de capital en mai 2026 pour un montant total d'environ 86,1 million d'euros bruts, incluant l'émission de bons de souscription préfinancés, pour accélérer le développement des autres [...]
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
02/06/2026
WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer [...]
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
Shopify Announces $3 Billion Increase to Share Repurchase Program
02/06/2026
Internet, Everywhere, June 02, 2026 (GLOBE NEWSWIRE) -- Shopify Inc. (NASDAQ, TSX: SHOP) today announced that its Board of Directors has authorized an additional $3 billion for the repurchase of Class A subordinate [...]
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
02/06/2026
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 90% vs historical [...]
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
02/06/2026
Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company’s other platforms New data from [...]
BriaCell Therapeutics Announces Closing of Offering
02/06/2026
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Alvotech to present at upcoming investor conferences in June
02/06/2026
REYKJAVIK, ICELAND (June 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Pages